Viking Therapeutics, Inc.VKTX
Market cap
$4B
P/E ratio
| Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Revenues | - | - | - | - | - | - | - | - | - | - |
| Research and development | 7 | 9 | 14 | 19 | 24 | 32 | 45 | 54 | 64 | 102 |
| General and administrative | 5 | 5 | 5 | 7 | 9 | 11 | 11 | 16 | 37 | 49 |
| Total operating expenses | 12 | 14 | 19 | 26 | 33 | 43 | 56 | 70 | 101 | 151 |
| Loss from operations | -11,996,478 | -13,847,275 | -19,070,189 | -26 | -33 | -43 | -56 | -70 | -101 | -151 |
| Amortization of financing costs | - | 138,701 | 571,044 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest income, net | -88,682 | -21,928 | 1,271 | 3 | 7 | 3 | 1 | 2 | 15 | 41 |
| Realized Investment Gains (Losses) | - | - | - | - | - | - | - | - | - | 0 |
| Total other income, net | -11,407,510 | -884,547 | -1,507,476 | 4 | 7 | 3 | 1 | 1 | 15 | 41 |
| Net loss | -23,403,988 | -14,731,822 | -20,577,665 | -22 | -26 | -39 | -55 | -69 | -86 | -110 |
| Unrealized gain (loss) on securities | -7,370 | 478 | -12,877 | -0 | 0 | -0 | -0 | -0 | 1 | -0 |
| Foreign currency translation loss | - | - | - | - | - | - | - | - | -0 | -0 |
| Comprehensive loss | -23,411,358 | -14,731,344 | -20,590,542 | -22 | -25 | -40 | -55 | -69 | -85 | -110 |
| Earnings Per Share, Basic | - | - | - | - | - | - | - | -0.9 | -0.91 | -1.01 |
| Earnings Per Share, Diluted | - | - | - | - | - | - | - | -0.9 | -0.91 | -1.01 |